Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Trastuzumab Deruxtecan + Stereotactische Radiotherapie (SRS) bij HER2+ Borstkanker Hersenmetastasen

29 september 2026 bijgewerkt door: Baptist Health South Florida

Fase 1-onderzoek van Trastuzumab Deruxtecan met stereotactische radiochirurgie (SRS) bij deelnemers met hersenmetastasen van HER-2-positieve borstkanker

A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  1. Histologically confirmed HER-2-positive breast cancer with newly diagnosed brain metastases.
  2. ECOG Performance Status (PS) of 0, 1, 2.
  3. Participants with 1-10 brain metastases will be candidates for T-DXd with SRS at the discretion of the treating radiation oncologist. Intra-cranial metastasis must measure 3 cm or less in the greatest dimension.
  4. Age ≥ 18 years
  5. Signed written informed consent by patient or legally authorized representative. A signed informed consent must be obtained prior to any study-specific procedures.
  6. Life expectancy of at least 12 weeks.
  7. Any number of prior systemic therapies will be allowed, except T-DXd.
  8. Hemoglobin ≥ 9 g/dL, White blood count ≥ 3.0 × 109/L, Absolute Neutrophil count ≥ 1.5 × 109/L and platelet count ≥ 100 × 109/L.
  9. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN).
  10. AST and/or ALT ≤ 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases).
  11. Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance > 60 mL/min.
  12. Ability to comply with study procedures and monitoring.
  13. For individuals of childbearing potential, a negative pregnancy test should be obtained within 7 days prior to the start of therapy.
  14. Participants must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before enrollment (to be assessed as clinically indicated).
  15. Male or female participants of reproductive potential need to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 7 months after last dose of T-DXd.

Highly effective and acceptable forms of contraception are:

  • Male condom plus spermicide
  • Cap plus spermicide
  • Diaphragm plus spermicide
  • Copper T
  • Progesterone T
  • Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
  • Implants
  • Hormone shot or injection
  • Combined pill
  • Mini-pill
  • Patch

Postmenopausal individuals on the study (that will not need contraception) is defined as:

  • Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments.
  • LH and FSH levels in the postmenopausal range for individuals < 50 years.
  • Radiation-induced oophorectomy with last menses > 1 year ago.
  • Chemotherapy-induced menopause with > 1 year interval since last menses.
  • Surgical sterilization (bilateral oophorectomy or hysterectomy).

Men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  1. Participants with leptomeningeal metastases documented by MRI or CSF evaluation.
  2. Evidence of intra-tumoral or peri-tumoral hemorrhage deemed clinically significant by the treating physician.
  3. Brain metastases within 5 mm of the optic chiasm or optic nerve.
  4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or CTCAE grade > 2 diarrhea of any etiology at baseline.
  5. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, New York Heart Association (NYHA) functional classification of 3 or 4.
  6. Unable to undergo brain MRI.
  7. Screen for human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. HIV/HBV/HCV testing per institutional practice.
  8. All toxicities from prior therapies must have resolved to CTCAE v5.0 grade 1 or better by the time of study enrollment.
  9. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active, or uncontrolled infection, uncontrolled diabetes, second active malignancy) that could cause unacceptable safety risks or compromise compliance with the protocol.
  10. Currently receiving other investigational cancer therapy (with the exception of continuing therapy with GnRH analogues) within 4 weeks prior to start of study treatment.
  11. Mean QT interval corrected heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms using Fredericia's Correction, calculated as: 8.22 ∛(RR interval)
  12. LVEF <50%.
  13. Ineligible for treatment with T-DXd.
  14. Ineligible for treatment with SRS.
  15. Active or prior documented ILD/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  16. History of hypersensitivity to T-DXd.
  17. History and/or confirmed corneal ulceration.
  18. Pregnant or breast feeding. The patients should not breast feed for 7 months after stopping the drug.
  19. Use of anthracyclines will be prohibited while on the protocol.
  20. Prior cranial radiation is not allowed.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: T-DXd + SRS

All participants will receive SRS and the drug T-DXd. The goal is to evaluate safety and determine an appropriate dose.

T-DXd will be given as an IV infusion every 21 days. This Phase 1 study will use predefined dose levels (5.4 mg/kg, 4.4 mg/kg, and 3.2 mg/kg) to evaluate safety and tolerability. Participants may continue treatment until disease progression, unacceptable side effects, or withdrawal.

Andere namen:
  • T-DXd

Participants will receive SRS to intact brain metastases. Typical dosing is 20-24 Gy in a single fraction for lesions <20 mm, or 27 Gy in 3 fractions for lesions ≥20 mm. Exact dosing will be based on the treating radiation oncologist's clinical judgment.

Andere namen:
  • SRS

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of dose-limiting toxicities (DLTs)
Tijdsspanne: 3 weeks

DLTs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 starting from the first dose of T-DXd through 3 weeks after SRS. DLT is defined as the appearance of side effects during treatment that are severe enough to prevent continuation of treatment at a participant's assigned dose. Any of the following events will be considered a DLT if treatment-related:

  • ≥ Grade 4 non-hematologic toxicity except nausea and vomiting (if manageable with supportive care measures), alopecia, drug-related fever, and toxicities secondary to neutropenia and sepsis
  • ≥ Grade 3 neurologic toxicity (sensory or autonomic)
  • Grade 4 platelet count (<25,000/mm³) 50 days beyond the start of the most recent chemotherapy (not related to recurrent leukemia)
  • Grade 4 neutropenia 50 days beyond the start of the most recent chemotherapy (not related to recurrent leukemia)
  • Grade 3 non-hematologic toxicity (excluding alopecia or toxicities secondary to neutropenia
3 weeks
Determination of the maximum tolerated dose (MTD) of T-DXd in combination with SRS
Tijdsspanne: 3 weeks

The MTD will be determined using a standard 3+3 dose de-escalation design across predefined dose levels of T-DXd (5.4 mg/kg, 4.4 mg/kg, and 3.2 mg/kg IV every 21 days), based on the number of participants who experience a DLT at each dose level.

3 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Intracranial Progression-free survival (PFS) at 6 months (PFS-6)
Tijdsspanne: 6 months

Intracranial PFS-6 will be defined as the time from first dose of study drug until intracranial disease progression (i.e., progression within the skull) or death from any cause using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at 6 months post-treatment. Progression is defined as at least 20% increase in the sum of the longest diameters of the target lesions, appearance of any new lesions, or unequivocable progression of any non-target lesions. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.

6 months
Extracranial PFS-6
Tijdsspanne: 6 months

Extracranial PFS-6 will be defined as the time from first dose of study drug until extracranial disease progression (i.e., progression outside of the skull) or death from any cause using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at 6 months post-treatment. Progression is defined as at least 20% increase in the sum of the longest diameters (LD) of the target lesions compared to the smallest recorded LD since treatment started, appearance of any new lesions, or unequivocable progression of any non-target lesions. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.

6 months
Overall survival (OS)
Tijdsspanne: 2 years

Median OS will be defined as the time from the beginning of study drug treatment until death due to any cause at the end of the study (~2 years). For participants who have not died at the time of the analysis, censoring will be performed using the date the participant was last known to be alive.

2 years
Objective response rate (ORR)
Tijdsspanne: 2 years

ORR will be defined as the proportion of participants achieving a complete response (CR) or partial response (PR) using RECIST v1.1 as their best overall response by the end of the study (~2 years). Participants with CR or PR will be counted as successes and all other participants (including those with missing response information) will be counted as failures. CR is defined as disappearance of all target and non-target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. All lymph nodes must be non-pathological in size (<10 mm short axis). PR is defined as at least 30% decrease in the sum of the LD of target lesions compared to baseline. There can be no appearance of new lesions.

2 years
Intracranial PFS-6 comparison to historical data
Tijdsspanne: 6 months

Intracranial PFS-6 as defined in Outcome 3 will be compared to historical data.

6 months
Extracranial PFS-6 comparison to historical data
Tijdsspanne: 6 months

Extracranial PFS-6 as defined in Outcome 4 will be compared to historical data.

6 months
OS comparison to historical data
Tijdsspanne: 2 years

Median OS as defined in Outcome 5 will be compared to historical data.

2 years
ORR comparison to historical data
Tijdsspanne: 2 years

ORR as defined in Outcome 6 will be compared to historical data.

2 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Manmeet Ahluwalia, Baptist Health Herbert Wertheim Cancer Institute

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 januari 2027

Primaire voltooiing (Geschat)

1 februari 2029

Studie voltooiing (Geschat)

1 februari 2030

Studieregistratiedata

Eerst ingediend

16 februari 2026

Eerst ingediend dat voldeed aan de QC-criteria

2 maart 2026

Eerst geplaatst (Werkelijk)

6 maart 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

29 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren